LATAM Hypoactive Sexual Desire Disorder (HSDD) Treatment Market by Treatment Type (Buspirone, Bupropion, Bremelanotide, and Flibanserin), Sales Channel (Hospitals, Clinics, and Online Retailers): Regional Opportunity Analysis and Industry Forecast, 2020–2027
The LATAM women hypoactive sexual desire disorder treatment market accounted for $967 million in 2019, and is expected to reach $1,275 million by 2027, registering a CAGR of 6.1% from 2020 to 2027.
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.
Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.
In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.
The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.
The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone, bupropion, bremelanotide, and flibanserin. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, it is classified into Brazil, Argentina, Chile, Colombia, and rest of the LATAM.
The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.
KEY BENEFITS FOR STAKEHOLDERS
Hypoactive sexual desire disorder (HSDD) is the most common type of sexual dysfunction that occurs in adult women globally, manifested by lack of sex interest for a period of six months or more, owing to personal distress or fluctuating sex hormones during menstrual cycle. Hypoactive sexual desire disorder is also known as female sexual interest/arousal disorder. HSDD is currently on the rise in adult women population, which causes low self-confidence and less connection with partners.
Hypoactive sexual desire disorder is classified into primary, secondary, acquired and generalized, or situational. Accurate diagnosis of symptoms of HSDD is very critical to finalize the treatment procedure, which is either psychotherapy or pharmacotherapy. Pharmacotherapy comprises buspirone and bupropion off label non hormonal treatment for HSDD in women suffering from low libido associated with anxiety and depression. Moreover, cognitive behavior therapy is suggested to patients showing a positive response to counseling sessions with a sex therapist.
In addition, Flibanserin is currently the only drug approved by the US FDA (Food & Drug Administration) for treating HSDD in premenopausal women, owing to its multifunctional serotonin agonist and antagonist pharmacodynamic profile.
The LATAM women hypoactive sexual desire disorder (HSDD) treatment market is expected to register substantial growth in the future, owing to rise in prevalence of lifestyle ailments, such as stress, depression, anxiety, and prolonged fatigue and rise in use of medicines, which induces the state of hypoactive sexual desire disorder. For instance, stress can lead to release of hormones such as cortisol and epinephrine. These hormones in high levels can lead to diminished sex drive. Similarly, depression is marked by depressed mood, decreased energy, and loss of interest in pleasurable activities. In addition, rise in number of surgical procedures, which leads to sexual dysfunction, are expected to boost the growth of LATAM women hypoactive sexual desire disorder treatment market during the forecast period. However, lack in awareness related to hypoactive sexual desire disorder are anticipated to hamper the market growth during the forecast period. For instance, For instance, there is a lack of public education on sexual health issues in many countries of Latin America such as Brazil and Guyana. This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in the coming years. Hence, the presence of pipeline drugs offers a lucrative opportunity for the LATAM women hypoactive sexual desire disorder treatment market.
The LATAM women hypoactive sexual desire disorder treatment market is segmented on the basis of treatment type, sales channel, and country. By treatment type, the market is categorized into buspirone, bupropion, bremelanotide, and flibanserin. On the basis of sales channel, it is divided into hospitals, clinics, and online retailers. Country wise, it is classified into Brazil, Argentina, Chile, Colombia, and rest of the LATAM.
The key players operating in the LATAM women hypoactive sexual desire disorder treatment market include Aurobindo Pharma, Bristol-Myers Squibb Company, Glaxo Smith Kline (GSK), Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceuticals, Novartis (Sandoz), Sun Pharmaceutical Industries Ltd., and Cadila Healthcare (Zydus). Product launch and acquisition were the most common strategies adopted by the key players, which has led to expansion of their product offerings.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global LATAM women hypoactive sexual desire disorder treatment market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessments.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Treatment Type
- Buspirone
- Bupropion
- Bremelanotide
- Flibanserin
- By Sales Channel
- Hospitals
- Clinics
- Online Retailers
- By Country
- Brazil
- Argentina
- Chile
- Colombia
- Rest of LATAM
- List of key players profiled in the report:
- Aurobindo Pharma
- Bristol-Myers Squibb Company
- GlaxoSmithKline Plc
- Mylan N.V.
- Novartis AG
- Palatin Technologies, Inc.
- Sprout Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceutical Industries Ltd.
- Zydus Cadila
- Shanghai Fosun Pharmaceutical Co., Ltd.
- Amneal Pharmaceuticals
- Allergan plc
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key Findings
3.2.1.Top Winning Strategies
3.2.2.Top investment pockets
3.3.Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
3.4.Top player positioning, 2019
3.5.Annual Spending, 2019
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Surge in prevalence of lifestyle ailments
3.6.1.2.Rise in use of medicines that induce hypoactive sexual desire disorder
3.6.1.3.Rise in number of surgical procedures leading to sexual dysfunction
3.6.2.Restraint
3.6.2.1.Lack in awareness related to hypoactive sexual desire disorder
3.6.3.Opportunity
3.6.3.1.Presence of strong pipeline products
3.7.Impact Analysis
3.8.COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
3.9.Cognitive Behavior Therapy
3.9.1.Key market trends, growth factors, and opportunities
3.9.2.Market analysis, by country
CHAPTER 4:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Buspirone
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country
4.3.Bupropion
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country
4.4.Bremelanotide
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country
4.5.Flibanserin
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market analysis, by country
CHAPTER 5:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Market analysis, by country
5.3.Clinics
5.3.1.Market analysis, by country
5.4.Online Retailers
5.4.1.Market analysis, by country
CHAPTER 6:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast, by country
6.2.Brazil
6.2.1.Key market trends and growth opportunities
6.2.2.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.2.3.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.3.Argentina
6.3.1.Key market trends and growth opportunities
6.3.2.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.3.3.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.4.Chile
6.4.1.Key market trends and growth opportunities
6.4.2.Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.4.3.Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.5.Colombia
6.5.1.Key market trends and growth opportunities
6.5.2.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.5.3.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.6.Rest of LATAM
6.6.1.Key market trends and growth opportunities
6.6.2.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.6.3.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
CHAPTER 7:COMPANY PROFILES
7.1.AUROBINDO PHARMA
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance.
7.2.BRISTOL-MYERS SQUIBB COMPANY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance
7.3.GLAXOSMITHKLINE PLC (GSK)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.
7.4.MYLAN N.V.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.NOVARTIS INTERNATIONAL AG
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.PALATIN TECHNOLOGIES, INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments
7.7.SPROUT PHARMACEUTICALS, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments
7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZYDUS CADILA
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key Findings
3.2.1.Top Winning Strategies
3.2.2.Top investment pockets
3.3.Key forces shaping LATAM women hypoactive sexual desire disorder treatment industry/market
3.4.Top player positioning, 2019
3.5.Annual Spending, 2019
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Surge in prevalence of lifestyle ailments
3.6.1.2.Rise in use of medicines that induce hypoactive sexual desire disorder
3.6.1.3.Rise in number of surgical procedures leading to sexual dysfunction
3.6.2.Restraint
3.6.2.1.Lack in awareness related to hypoactive sexual desire disorder
3.6.3.Opportunity
3.6.3.1.Presence of strong pipeline products
3.7.Impact Analysis
3.8.COVID-19 Impact Analysis on LATAM women hypoactive sexual desire disorder treatment market
3.9.Cognitive Behavior Therapy
3.9.1.Key market trends, growth factors, and opportunities
3.9.2.Market analysis, by country
CHAPTER 4:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Buspirone
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market analysis, by country
4.3.Bupropion
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market analysis, by country
4.4.Bremelanotide
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market analysis, by country
4.5.Flibanserin
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market analysis, by country
CHAPTER 5:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospitals
5.2.1.Market analysis, by country
5.3.Clinics
5.3.1.Market analysis, by country
5.4.Online Retailers
5.4.1.Market analysis, by country
CHAPTER 6:LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY COUNTRY
6.1.Overview
6.1.1.Market size and forecast, by country
6.2.Brazil
6.2.1.Key market trends and growth opportunities
6.2.2.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.2.3.Brazil hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.3.Argentina
6.3.1.Key market trends and growth opportunities
6.3.2.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.3.3.Argentina hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.4.Chile
6.4.1.Key market trends and growth opportunities
6.4.2.Chile hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.4.3.Chile hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.5.Colombia
6.5.1.Key market trends and growth opportunities
6.5.2.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.5.3.Colombia hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
6.6.Rest of LATAM
6.6.1.Key market trends and growth opportunities
6.6.2.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by treatment type
6.6.3.Rest of LATAM women hypoactive sexual desire disorder (HSDD) treatment market, by sales channel
CHAPTER 7:COMPANY PROFILES
7.1.AUROBINDO PHARMA
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance.
7.2.BRISTOL-MYERS SQUIBB COMPANY
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product Portfolio
7.2.5.Business performance
7.3.GLAXOSMITHKLINE PLC (GSK)
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.
7.4.MYLAN N.V.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.NOVARTIS INTERNATIONAL AG
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.6.PALATIN TECHNOLOGIES, INC.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments
7.7.SPROUT PHARMACEUTICALS, INC.
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments
7.8.SUN PHARMACEUTICAL INDUSTRIES LIMITED
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.9.TEVA PHARMACEUTICAL INDUSTRIES LTD. (ACTAVIS GENERICS)
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.10.ZYDUS CADILA
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance.
LIST OF TABLES
TABLE 01.ANNUAL SPENDING ON WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT, BY COUNTRY, 2019 (US$)
TABLE 02.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 (NUMBER OF SESSIONS)
TABLE 04.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 05.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 06.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 08.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 10.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 12.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 14.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 15.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 16.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 18.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 20.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 22.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 25.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 26.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 27.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 28.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 29.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 30.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 32.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 33.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 34.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 35.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 36.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 37.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 38.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 39.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 40.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 41.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 42.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 43.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 44.AUROBINDO: COMPANY SNAPSHOT
TABLE 45.AUROBINDO: PRODUCT PORTFOLIO
TABLE 46.BMS: COMPANY SNAPSHOT
TABLE 47.BMS: PRODUCT PORTFOLIO
TABLE 48.GSK: COMPANY SNAPSHOT
TABLE 49.GSK: OPERATING SEGMENTS
TABLE 50.GSK: PRODUCT PORTFOLIO
TABLE 51.MYLAN: COMPANY SNAPSHOT
TABLE 52.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 53.MYLAN: PRODUCT PORTFOLIO
TABLE 54.NOVARTIS: COMPANY SNAPSHOT
TABLE 55.NOVARTIS: OPERATING SEGMENTS
TABLE 56.NOVARTIS: PRODUCT PORTFOLIO
TABLE 57.PALATIN: COMPANY SNAPSHOT
TABLE 58.PALATIN: PRODUCT PORTFOLIO
TABLE 59.SPROUT: COMPANY SNAPSHOT
TABLE 60.SPROUT: OPERATING SEGMENTS
TABLE 61.SPROUT: PRODUCT PORTFOLIO
TABLE 62.SPROUT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.SUN PHARMA: COMPANY SNAPSHOT
TABLE 64.SUN PHARMA: OPERATING SEGMENTS
TABLE 65.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 66.TEVA: COMPANY SNAPSHOT
TABLE 67.TEVA: OPERATING SEGMENTS
TABLE 68.TEVA: PRODUCT PORTFOLIO
TABLE 69.ZYDUS: COMPANY SNAPSHOT
TABLE 70.ZYDUS: OPERATING SEGMENTS
TABLE 71.ZYDUS: PRODUCT PORTFOLIO
TABLE 01.ANNUAL SPENDING ON WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT, BY COUNTRY, 2019 (US$)
TABLE 02.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 03.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR COGNITIVE BEHAVIOR THERAPY, BY COUNTRY, 2019–2027 (NUMBER OF SESSIONS)
TABLE 04.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 05.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 06.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 07.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUSPIRONE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 08.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 09.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BUPROPION, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 10.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 11.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR BREMELANOTIDE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 12.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 13.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR FLIBANSERIN, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 14.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 15.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 16.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 17.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR HOSPITALS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 18.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR CLINICS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 20.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET FOR ONLINE RETAILERS, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 22.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET REVENUE, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 25.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 26.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 27.BRAZIL HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 28.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 29.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 30.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 31.ARGENTINA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 32.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 33.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 34.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 35.CHILE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 36.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 37.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 38.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 39.COLOMBIA HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 40.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 ($MILLION)
TABLE 41.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY TREATMENT TYPE, 2019–2027 (MILLION UNITS)
TABLE 42.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 ($MILLION)
TABLE 43.REST OF LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) TREATMENT MARKET, BY SALES CHANNEL, 2019–2027 (MILLION UNITS)
TABLE 44.AUROBINDO: COMPANY SNAPSHOT
TABLE 45.AUROBINDO: PRODUCT PORTFOLIO
TABLE 46.BMS: COMPANY SNAPSHOT
TABLE 47.BMS: PRODUCT PORTFOLIO
TABLE 48.GSK: COMPANY SNAPSHOT
TABLE 49.GSK: OPERATING SEGMENTS
TABLE 50.GSK: PRODUCT PORTFOLIO
TABLE 51.MYLAN: COMPANY SNAPSHOT
TABLE 52.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 53.MYLAN: PRODUCT PORTFOLIO
TABLE 54.NOVARTIS: COMPANY SNAPSHOT
TABLE 55.NOVARTIS: OPERATING SEGMENTS
TABLE 56.NOVARTIS: PRODUCT PORTFOLIO
TABLE 57.PALATIN: COMPANY SNAPSHOT
TABLE 58.PALATIN: PRODUCT PORTFOLIO
TABLE 59.SPROUT: COMPANY SNAPSHOT
TABLE 60.SPROUT: OPERATING SEGMENTS
TABLE 61.SPROUT: PRODUCT PORTFOLIO
TABLE 62.SPROUT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 63.SUN PHARMA: COMPANY SNAPSHOT
TABLE 64.SUN PHARMA: OPERATING SEGMENTS
TABLE 65.SUN PHARMA: PRODUCT PORTFOLIO
TABLE 66.TEVA: COMPANY SNAPSHOT
TABLE 67.TEVA: OPERATING SEGMENTS
TABLE 68.TEVA: PRODUCT PORTFOLIO
TABLE 69.ZYDUS: COMPANY SNAPSHOT
TABLE 70.ZYDUS: OPERATING SEGMENTS
TABLE 71.ZYDUS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET SEGMENTATION:
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 04.LOW BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTES
FIGURE 06.HIGH INTENSITY OF RIVALRY
FIGURE 07.MODERATE THREAT OF NEW ENTRANT
FIGURE 08.TOP PLAYER POSITIONING, 2019
FIGURE 09.IMPACT ANALYSIS, LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET
FIGURE 10.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 11.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 12.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 14.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 21.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 22.PALATIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 25.SUN PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2020 (%)
FIGURE 26.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 01.LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET SEGMENTATION:
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 04.LOW BARGAINING POWER OF BUYERS
FIGURE 05.LOW THREAT OF SUBSTITUTES
FIGURE 06.HIGH INTENSITY OF RIVALRY
FIGURE 07.MODERATE THREAT OF NEW ENTRANT
FIGURE 08.TOP PLAYER POSITIONING, 2019
FIGURE 09.IMPACT ANALYSIS, LATAM WOMEN HYPOACTIVE SEXUAL DESIRE DISORDER TREATMENT MARKET
FIGURE 10.AUROBINDO: NET SALES, 2018–2020 ($MILLION)
FIGURE 11.AUROBINDO: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 12.BMS: NET SALES, 2017–2019 ($MILLION)
FIGURE 13.BMS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 14.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 15.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 16.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 17.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 18.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 19.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 20.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 21.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 22.PALATIN: NET SALES, 2018–2020 ($MILLION)
FIGURE 23.SUN PHARMA: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.SUN PHARMA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 25.SUN PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2020 (%)
FIGURE 26.TEVA: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.TEVA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.TEVA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ZYDUS: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.ZYDUS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.ZYDUS: REVENUE SHARE, BY REGION, 2020 (%)
